Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 4, 2009, Pages 432-438

  Castagna, Luca ^a   Sarina, Barbara ^a   Todisco, Elisabetta ^a   Magagnoli, Massimo ^a   Balzarotti, Monica ^a   Bramanti, Stefania ^a   Mazza, Rita ^a   Anastasia, Antonella ^a   Bacigalupo, Andrea ^b   Aversa, Franco ^c   Soligo, Davide ^d   Giordano, Laura ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Allogeneic transplantation; High dose chemotherapy; Hodgkin lymphoma; Salvage chemotherapy

Indexed keywords

ALEMTUZUMAB; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAVELBINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; THIOTEPA; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HLA MATCHING; HODGKIN DISEASE; HUMAN; LIVING DONOR; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RISK ASSESSMENT; SIBLING; SURVIVAL TIME;

ADOLESCENT; ADULT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELLS; HODGKIN DISEASE; HUMANS; LIVING DONORS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 61749102653     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.12.506     Document Type: Article

References (38)

1. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 34 (1993) 1051-1054
2. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359 (2002) 2065-2071
3. Brice P., Bouabdallah R., Moreau P., et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant 20 (1997) 21-26
4. Sureda A., Arranz R., Iriondo A., et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol 19 (2001) 1395-1404
5. Shamash J., Lee S.M., Radford J.A., et al. Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. Ann Oncol 11 (2000) 715-719
6. Bolwell B.J., Kalaycio M., Goormastic M., et al. Progressive disease after ABMT for Hodgkin's disease. Bone Marrow Transplant 20 (1997) 761-765
7. De Lima M., van Besien K.W., Giralt S.A., et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 19 (1997) 121-127
8. Tsai T., Goodman S., Saez R., et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 10 (1997) 859-863
9. Vose J.M., Bierman P.J., Anderson J.R., et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80 (1992) 2142-2148
10. Little R., Wittes R.E., Longo D.L., and Wilson W.H. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol 16 (1998) 584-588
11. Santoro A., Bredenfeld H., Devizzi L., et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 18 (2000) 2615-2619
12. Devizzi L., Santoro A., Bonfante V., et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 5 (1994) 817-820
13. Lin T.S., Avalos B.R., Penza S.L., Marcucci G., Elder P.J., and Copelan E.A. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease. Bone Marrow Transplant 29 (2002) 763-767
14. Anderson J.E., Litzow M.R., Appelbaum F.R., et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 11 (1993) 2342-2350
15. Milpied N., Fielding A.K., Pearce R.M., Ernst P., and Goldstone A.H. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14 (1996) 1291-1296
16. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 (2002) 4310-4316
17. Peggs K.S., Hunter A., Chopra R., et al. Clinical evidence of a graft-versus-Hodgkin's lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365 (2005) 1934-1941
18. Anderlini P., Saliba R., Acholonu S., et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35 (2005) 943-951
19. Santoro A., Magagnoli M., Spina M., et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 92 (2007) 35-41
20. Castagna L., Magagnoli M., Balzarotti M., et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a prospective study from a single institution. Am J Hematol 82 (2007) 122-127
21. Todisco E., Castagna L., Sarina B., et al. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Eur J Hematol 78 (2007) 322-329
22. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 3447-3454
23. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
24. Lee S.J., Vogelsang G., and Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 9 (2003) 215-233
25. Sullivan K.M., Witherspoon R.P., Storb R., et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 72 (1988) 555-561
26. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (2003) 1244-1253
27. Varterasian M., Ratanatharathorn V., Uberti J.P., et al. Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation. Leuk Lymph 20 (1995) 59-65
28. Vandenberghe E., Pearce R., Taghipour G., Fouillard G., and Goldstone A.H. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. J Clin Oncol 15 (1997) 1595-1600
29. Sureda A., Robinson S., Canals C., et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26 (2008) 455-462
30. Sureda A., Caballero M.D., Urbano-Ispizua A., et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 12 (2006) 172-183
31. Anderlini P., Saliba R., Acholonu S., et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93 (2008) 257-264
32. Schmitz N., Dreger P., Glass B., and Sureda A. Allogeneic transplantation in lymphoma: current status. Haematologica 92 (2007) 1533-1548
33. Thomson K.J., Peggs K.S., Smith P., et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 41 (2008) 765-770
34. Ardeshna K.M., Kakouros N., Qian W., et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol 130 (2005) 363-372
35. Peggs K.S., Sureda A., Qian W., et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 139 (2007) 70-80
36. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102 (2003) 53-59
37. Jabbour E., Hosing C., Ayers G., et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109 (2007) 2481-2489
38. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 110 (2007) 2744-2748